Chronic Obstructive Pulmonary Disease
Conditions
Interventions
We evaluate the result after the patients inhaled tiotropium for four weeks. Then, we switch from tiotropium to indicaterol, observe the progress for four weeks, and evaluate the result.
We evaluate t
Sponsors
Showa University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)A Patient who is visiting our outpatient clinic, is over 40 years of age, and has smoking history 2)A patient who is classified into the second or third stage of COPD in pulmonary function test. 3)A patient who smoke 1 pack per day for 10 years or more 4)A patient who agreed to participate in the study with the written informed consent
Exclusion criteria
Exclusion criteria: 1)A patient who cannot be performed a respiratory function test appropriately 2)A Patients with asthma. 3)A patients who have has experienced an acute COPD exacerbation or respiratory tract infection within the past 4 weeks prior to the informed consent 4)A patients with advanced malignant tumor 5)A patients who are is pregnant 6)A patients who are is allergic to tiotropium or ipratropium 7)A patients receiving oxygen inhalation for more than 15 hours/day 8) A patient whom the doctor in charge judged unsuitable as subjected is excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the background factors of the patients who showed significant differences through a pulmonary function test four weeks after the intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the background factors of the patients who showed significant differences through CAT, TDI and IPAQ four weeks after the intervention. | — |
Countries
Japan
Contacts
Public ContactKuniaki Hirai
Showa University School of Medicine Division of Allergology and Respiratory Medicine
Outcome results
None listed